164 related articles for article (PubMed ID: 2028445)
1. Inhibition of PAF-induced human platelet responses by newly synthesized ether phospholipids.
Ostermann G; Hofmann B; Kertscher HP; Till U
Thromb Res; 1991 Feb; 61(3):261-9. PubMed ID: 2028445
[TBL] [Abstract][Full Text] [Related]
2. Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
Ostermann G; Hofmann B; Kertscher HP; Till U
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):713-8. PubMed ID: 2096302
[TBL] [Abstract][Full Text] [Related]
3. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. II. Relationships between chemical structure and inhibition of PAF-induced human platelet activation.
Ostermann G; Hofmann B; Kertscher HP; Till U
J Lipid Mediat; 1991; 3(2):225-37. PubMed ID: 1797154
[TBL] [Abstract][Full Text] [Related]
4. Effect of synthetic phospholipids on platelet aggregation and serotonin release.
Söling U; Eibl H; Nagel GA; Unger C
Lipids; 1987 Nov; 22(11):868-70. PubMed ID: 3444380
[TBL] [Abstract][Full Text] [Related]
5. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
[TBL] [Abstract][Full Text] [Related]
6. Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets.
Hofmann B; Ostermann G; Kertscher HP; Till U
Thromb Res; 1988 Feb; 49(4):415-23. PubMed ID: 3381200
[TBL] [Abstract][Full Text] [Related]
7. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. I. Studies on blood platelets in vitro.
Ostermann G; Hofmann B; Kertscher HP; Till U
J Lipid Mediat; 1990; 2(1):21-31. PubMed ID: 1966804
[TBL] [Abstract][Full Text] [Related]
8. Two different sites of action for platelet activating factor and 1-O-alkyl-2-O-methyl-sn-glycero-3-phosphocholine on platelets and leukemic cells.
Salari H; Dryden P; Howard S; Bittman R
Biochem Cell Biol; 1992 Feb; 70(2):129-35. PubMed ID: 1324692
[TBL] [Abstract][Full Text] [Related]
9. Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists.
Tokumura A; Yoshida J; Okasaka N; Fukuzawa K; Tsukatani H
Thromb Res; 1987 Apr; 46(1):153-61. PubMed ID: 3590110
[TBL] [Abstract][Full Text] [Related]
10. CV-3988 - a specific antagonist of platelet activating factor (PAF).
Terashita Z; Tsushima S; Yoshioka Y; Nomura H; Inada Y; Nishikawa K
Life Sci; 1983 Apr; 32(17):1975-82. PubMed ID: 6403793
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of [3H]platelet activating factor (PAF) binding by Zn2+: a possible explanation for its specific PAF antiaggregating effects in human platelets.
Nunez D; Kumar R; Hanahan DJ
Arch Biochem Biophys; 1989 Aug; 272(2):466-75. PubMed ID: 2502069
[TBL] [Abstract][Full Text] [Related]
12. Xanthines inhibit human platelet aggregation induced by platelet-activating factor.
Misso NL; Thompson PJ
Clin Exp Pharmacol Physiol; 1992 Aug; 19(8):599-602. PubMed ID: 1526066
[TBL] [Abstract][Full Text] [Related]
13. Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF.
Porta C; Maiolo A; Tua A; Grignani G
Haematologica; 2000 Aug; 85(8):820-5. PubMed ID: 10942928
[TBL] [Abstract][Full Text] [Related]
14. Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor.
Ostermann G; Till U; Thielmann K
Thromb Res; 1983 Apr; 30(2):127-36. PubMed ID: 6408754
[TBL] [Abstract][Full Text] [Related]
15. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.
Nunez D; Chignard M; Korth R; Le Couedic JP; Norel X; Spinnewyn B; Braquet P; Benveniste J
Eur J Pharmacol; 1986 Apr; 123(2):197-205. PubMed ID: 3086108
[TBL] [Abstract][Full Text] [Related]
16. Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines.
Kornecki E; Ehrlich YH; Lenox RH
Science; 1984 Dec; 226(4681):1454-6. PubMed ID: 6150550
[TBL] [Abstract][Full Text] [Related]
17. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PAF-induced human platelet aggregation by antithrombotic nipecotomides.
Herron D; Dillingham EO; Lyman BA; Zheng X; Bond SE; Salgia SR; Gollamudi R
Prostaglandins Leukot Essent Fatty Acids; 1995 May; 52(5):309-18. PubMed ID: 7630919
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of novel steroid-modified ether phospholipids.
Karantonis HC; Pitsinos EN; Antonopoulou S; Couladouros EA; Demopoulos CA
Chem Phys Lipids; 2005 Dec; 138(1-2):12-9. PubMed ID: 16202400
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by glaucocalyxin A of aggregation of rabbit platelets induced by ADP, arachidonic acid and platelet-activating factor, and inhibition of [3H]-PAF binding.
Bin Z; Kun L
Thromb Haemost; 1992 Apr; 67(4):458-60. PubMed ID: 1631795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
